Elisa Garde-Lapido

Elisa Garde-Lapido

Auto-generated profile, based on publicly available information

Elisa Garde-Lapido

Department of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institutet

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LSLourdes Sainero-Alcolado
Lourdes Sainero-Alcolado
EGElisa Garde-Lapido
Elisa Garde-Lapido
MSMarteinn Thor Snaebjörnsson
Marteinn Thor Snaebjörnsson
SSSarah Schoch
Sarah Schoch
ISIrene Stevens
Irene Stevens
MAMarie Arsenian-Henriksson
Marie Arsenian-Henriksson
Metabolic reprogramming is critical during clear cell renal cell carcinoma (ccRCC) tumorigenesis, manifested by accumulation of lipid droplets (LDs), organelles that have emerged as new hallmarks of cancer. Yet, regulation of their biogenesis is still poorly understood. Here, we demonstrate that MYC inhibition in ccRCC cells lacking the von Hippel Lindau ( VHL ) gene leads to increased triglyceride content potentiating LD formation in a glutamine-dependent manner. Importantly, the concurrent inhibition of MYC signaling and glutamine metabolism prevented LD accumulation and reduced tumor burden in vivo. Furthermore, we identified the hypoxia-inducible lipid droplet–associated protein (HILPDA) as the key driver for induction of MYC-driven LD accumulation and demonstrated that conversely, proliferation, LD formation, and tumor growth are impaired upon its downregulation. Finally, analysis of ccRCC tissue as well as healthy renal control samples postulated HILPDA as a specific ccRCC biomarker. Together, these results provide an attractive approach for development of alternative therapeutic interventions for the treatment of this type of renal cancer.

18 June 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JPJudit Liano Pons
Judit Liano Pons
EGElisa Garde-Lapido
Elisa Garde-Lapido
FFFenja L. Fahrig
Fenja L. Fahrig
MJMerle Jäckering
Merle Jäckering
YYYe Yuan
Ye Yuan
MAMarie Arsenian-Henriksson
Marie Arsenian-Henriksson
Neuroblastoma (NB) is a heterogeneous childhood cancer, characterized by the amplification of the MYCN oncogene in 40% of the high-risk cases. Our previous work demonstrated that MYCN drives metabolic reprogramming in NB, including upregulation of antioxidant enzymes. Here, we identify peroxiredoxin 6 (PRDX6) as a promising therapeutic target in NB. Pharmacological inhibition of PRDX6 reduces MYCN levels, induces apoptosis, and promotes neuronal differentiation accompanied by lipid droplet accumulation, essential for the phenotypic reprogramming. Moreover, combined inhibition of PRDX6 and glutathione S-transferase Pi 1 (GSTP1), a key antioxidant enzyme needed for PRDX6 activation, demonstrated synergistic effects both in vitro and in vivo. This strategy results in neuronal maturation and initiates downstream pathways distinct from the ones triggered by retinoic acid, the differentiation-inducing agent currently used in clinical practice for NB. Notably, both PRDX6 and GSTP1 are highly expressed in the developing murine adrenal gland, as well as in high-risk, MYCN -amplified NB, correlating with an undifferentiated state and poor prognosis. Together, our results provide insights into the potential of PRDX6 and GSTP1 as therapeutic targets for differentiation induction for children with NB.